Key terms
About IPHA
Innate Pharma SA is a biopharmaceutical company, which engages in improving oncology treatment and clinical outcomes for patients through therapeutic antibodies that harness the immune system to fight cancer. Its product pipeline include Lacutamab, Monalizumab, Avdoralimab, and IPH62. The company was founded by Hervé Eloi Dominique Brailly, Eric Vivier, Marc Bonneville, Alessandro Moretta, Jean-Jacques Fournié, and François Romagné on September 23, 1999 and is headquartered in Marseille, France.
Sector
Industry
Employees
Founded
Website
Key stock statistics
1-day range
52-week range
Market cap
P/E ratio
Next earnings date
Dividend yield
Ex-dividend date
Dividend pay date
Key terms
Ad Feedback
Smart score
Latest IPHA news
Mar 26
4:45pm ET
Innate Pharma SA: A Balanced Hold Rating Amidst Clinical Setbacks and Cautious Optimism
Mar 22
6:27am ET
Innate Pharma: A Strong Buy on Promising Clinical Progress and Solid Financials
Mar 06
5:39am ET
Innate Pharma announces first patient dosed in IPH6501 trial
Feb 03
8:35pm ET
Innate Pharma SA (IPHYF) Receives a Hold from Kepler Capital
Jan 04
5:29am ET
Innate Pharma announces Yannis Morel broadens remit to COO
Jan 04
5:24am ET
Innate Pharma announces FDA lifts clinical hold on lacutamab IND
No recent news articles are available for IPHA
No recent press releases are available for IPHA
IPHA Financials
Key terms
Ad Feedback
IPHA Forecasts
analyst rating
- buy
- hold
- sell
1-year stock price forecast
IPHA Competitors
$ Market cap
P/E ratio
$ Price
1d change
52-week range